Is it Time to Go Bottom Fishing With This Cannabis Stock?

Why do you need to buy The Green Organic Dutchman Ltd (TSX:TGOD) stock right now.

Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Green Organic Dutchman (TSX:TGOD) was listed as a public company in April 2018. The euphoria about cannabis legalization in Canada drove TGOD stock from $4.12 in April 2018 to $10.2 in September 2018. However, cannabis stocks have experienced a massive correction in the last 12 months.

Now, TGOD is trading at $2.95 per share, which is 35% above its 52-week low and 71% below its 52-week high. Now, with the next wave of edibles legalization just a few days away, it is possible for cannabis stocks to move higher again, as investor optimism rises. So, do you buy TGOD shares? Let’s have a look at the company’s revenue and earnings growth as well as its valuation to see if it’s a good buy at the current price

Revenue growth is estimated at a staggering 1,843%

Analysts expect TGOD to post revenue of $36.51 million in 2019, a year-over-year growth of 1,843%. Sales are then estimated to rise by 515.5% to $224.71 million in 2020. While still unprofitable, TGOD will be improving the bottom line at a robust rate.

Analysts expect the net margin to improve from -162% in 2019 to 19.2% in 2020. Its EBITDA is estimated to rise from -$43.9 million in 2019 to $106 million in 2021. TGOD is valued at $752.1 million, which is 21 times its 2019 sales and in line with peer cannabis companies.

Why will TGOD become a major cannabis player?

Green Organic Dutchman has raised $465 million to date with a focus on rapid expansion. It has planned manufacturing capacity of 219,000 kg. The company has a 1.47 million square feet of hybrid greenhouses and processing facilities under construction in Canada. It is planning to have 167,000 square feet of manufacturing capacity in Europe and Jamaica.

Similar to other cannabis companies, TGOD will focus on international expansion to drive sales. Its currently focused on gaining traction in Jamaica, Denmark, Poland, and Mexico. TGOD has secured licensing deals in Canada and international markets and has a vibrant consumer-driven product portfolio.

The company has valued the medical market at $758 million and the recreational market at $5.7 billion.

Strong distribution network

TGOD has partnered with Velvet Management Inc., which is a leading cannabis sales and marketing agency. Velvet Management was established by Philippe Dandurand Wines, which is the largest wine distributor in Canada.

TGOD recently completed its first supply order to the Ontario Retail Cannabis Corp. It has supply agreements with The BC Liquor Distribution Branch and The Alberta Gaming, Liquor & Cannabis Commission.

The biggest driver for TGOD sales will be its entry into the U.S. markets next year. It has partnered with billion-dollar ingredient heavyweight Symrise to create Califormulations which is a U.S.-based beverage innovation company. Symrise provides companies with beverage commercialization support, technical services, and contract manufacturing co-ordination services.

It has also partnered with Jamaican market leader Epican Medicinals. The latter is a vertically integrated company with licences for cultivation, extraction, manufacturing, and retail distribution of cannabis products.

The verdict

While it might seem like TGOD is just another unprofitable high growth cannabis company, it is growing sales at an astounding rate via partnerships. It is expected to be profitable in the near future. TGOD is a good bet, as it seems that cannabis stocks should move higher significantly, at least till edibles are legalized.

Analysts have a 12-month price target of $5.23 for TGOD. This indicates that the stock is trading at a discount of 77% to the average target estimate.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »